corrections   an article in business day on saturday, about efforts by the drug maker bristol-myers squibb to recover from a competitive challenge to its best-selling blood thinner, plavix, misstated the board's position on potential merger or takeover deals involving the company. while bristol-myers executives have said repeatedly that they would be open to considering such deals, the board has not actively pursued a merger or sale.  